Search
Cartesian Therapeutics Inc
RNACAdd to Watchlist
10.590USD
+0.410+4.03%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
275.38MMarket Cap
LossP/E TTM
More Details of Cartesian Therapeutics Inc Company
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Cartesian Therapeutics Inc Info
Ticker SymbolRNAC
Company nameCartesian Therapeutics Inc
IPO dateJun 22, 2016
CEOBrunn (Carsten)
Number of employees66
Security typeOrdinary Share
Fiscal year-endJun 22
Address7495 New Horizon Way
CityFREDERICK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code21703
Phone13013488698
Websitehttps://www.cartesiantherapeutics.com/
Ticker SymbolRNAC
IPO dateJun 22, 2016
CEOBrunn (Carsten)
Company Executives of Cartesian Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
520.71K
+3.01%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
75.95K
+31.60%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
59.64K
-150.98%
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
27.32K
-41.36%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
8.43K
-380.76%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Lead Independent Director
Lead Independent Director
8.40K
+23.56%
Dr. Kemal Malik
Dr. Kemal Malik
Independent Director
Independent Director
4.58K
+43.19%
Mr. Timothy C. (Tim) Barabe
Mr. Timothy C. (Tim) Barabe
Independent Director
Independent Director
--
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Director
Director
--
--
Dr. Nishan M. de Silva, M.D.
Dr. Nishan M. de Silva, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
520.71K
+3.01%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
75.95K
+31.60%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
59.64K
-150.98%
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
27.32K
-41.36%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
8.43K
-380.76%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Lead Independent Director
Lead Independent Director
8.40K
+23.56%
FAQs
Who are the top five shareholders of Cartesian Therapeutics Inc?
The top five shareholders of Cartesian Therapeutics Inc are: Dr. Murat Kalayoglu, M.D., Ph.D.
How many institutions hold shares of Cartesian Therapeutics Inc (RNAC)?
As of 2026Q1, 191 institutions hold shares of Cartesian Therapeutics Inc, with a combined market value of approximately 7.99M, accounting for 27.21% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 636405.00.